Argent BioPharma Limited
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I c… Read more
Argent BioPharma Limited (RGTLF) - Net Assets
Latest net assets as of June 2025: $-8.63 Million USD
Based on the latest financial reports, Argent BioPharma Limited (RGTLF) has net assets worth $-8.63 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.47 Million) and total liabilities ($11.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.63 Million |
| % of Total Assets | -349.72% |
| Annual Growth Rate | N/A |
| 5-Year Change | -162.42% |
| 10-Year Change | N/A |
| Growth Volatility | 250.97 |
Argent BioPharma Limited - Net Assets Trend (2020–2025)
This chart illustrates how Argent BioPharma Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Argent BioPharma Limited (2020–2025)
The table below shows the annual net assets of Argent BioPharma Limited from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $-8.63 Million | -48.16% |
| 2024-06-30 | $-5.82 Million | +27.48% |
| 2023-06-30 | $-8.03 Million | -255.06% |
| 2022-06-30 | $5.18 Million | -62.54% |
| 2021-06-30 | $13.83 Million | +346.81% |
| 2020-06-30 | $3.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Argent BioPharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8538480000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $138.88 Million | % |
| Total Equity | $-8.63 Million | 100.00% |
Argent BioPharma Limited Competitors by Market Cap
The table below lists competitors of Argent BioPharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
I2 Enterprise Public Company Limited
BK:I2
|
$1.98 Million |
|
Cover Technologies Inc
PINK:MGPRF
|
$1.98 Million |
|
Bluechiip Ltd
AU:BCT
|
$1.98 Million |
|
Xin Hwa Holdings Bhd
KLSE:5267
|
$1.98 Million |
|
CDRL SA
WAR:CDL
|
$1.98 Million |
|
AMD Industries Limited
NSE:AMDIND
|
$1.98 Million |
|
H2 Ventures 1 Inc.
V:HO-P
|
$1.98 Million |
|
Jacob Finance And Investments Ltd
TA:JCFN
|
$1.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Argent BioPharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -5,152,448 to -8,629,925, a change of -3,477,477.
- Net loss of 17,844,295 reduced equity.
- New share issuances of 10,399,109 increased equity.
- Other factors increased equity by 3,967,709.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.84 Million | -206.77% |
| Share Issuances | $10.40 Million | +120.5% |
| Other Changes | $3.97 Million | +45.98% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Argent BioPharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-06-30 | $1.97 | $0.06 | x |
| 2021-06-30 | $5.96 | $0.06 | x |
| 2022-06-30 | $2.27 | $0.06 | x |
| 2023-06-30 | $-2.21 | $0.06 | x |
| 2024-06-30 | $-0.11 | $0.06 | x |
| 2025-06-30 | $-0.12 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Argent BioPharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3058.43%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-170.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -623.55% | -931.29% | 0.26x | 2.55x | $-19.67 Million |
| 2021 | -114.71% | -535.62% | 0.12x | 1.75x | $-17.25 Million |
| 2022 | -287.21% | -354.31% | 0.25x | 3.18x | $-17.35 Million |
| 2023 | 0.00% | -614.71% | 0.34x | 0.00x | $-20.08 Million |
| 2024 | 0.00% | -1967.34% | 0.08x | 0.00x | $-17.02 Million |
| 2025 | 0.00% | -3058.43% | 0.24x | 0.00x | $-16.98 Million |
Industry Comparison
This section compares Argent BioPharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Argent BioPharma Limited (RGTLF) | $-8.63 Million | -623.55% | N/A | $1.98 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |